- Home
- ENTX vs OFS Comparison
ENTX vs OFS Comparison
Compare ENTX & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTX | OFS |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | Israel | United States |
| Employees | N/A | 47 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 46.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ENTX | OFS |
|---|---|---|
| Price | $1.19 | $3.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 187.3K | 150.8K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 18.99% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $4.76 | $17.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $2.72 |
| 52 Week High | $3.22 | $9.31 |
Technical Indicators
Market Signals| Indicator | ENTX | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 50.35 |
| Support Level | $0.96 | $2.72 |
| Resistance Level | $1.61 | $5.33 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 46.15 | 84.34 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.